# US 2014/0193412 A1 · Treatment of cutaneous wounds by inhibiting cold shock proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193412 A1
- Document ID: US20140193412A1
- Status: Published application
- Kind: A1
- Application number: 14/152,091
- Filed: 2014-01-10
- Published: 2014-07-10
- Earliest claimed: 2013-01-10
- Assignees: The Feinstein Institute for Medical Research
- Applicants: The Feinstein Institute for Medical Research
- Inventors: Ping Wang; Weng-Lang Yang
- Web page: https://patentgrep.com/patent/US20140193412A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 38/1709: {from mammals}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are methods of treating a subject suffering from a cutaneous wound comprising administering to the subject a CIRP inhibitor.

## Claims

### Claim 1

A method of treating a subject suffering from a cutaneous wound, comprising administering to the subject an effective amount of a CIRP inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cutaneous wound is a chronic cutaneous wound.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cutaneous wound is a diabetic ulcer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cutaneous wound is a bed sore.

### Claim 5 (depends on 1)

The method of claim 1, wherein the CIRP inhibitor is an antibody or a functional fragment thereof that specifically binds to CIRP, wherein said antibody inhibits one or more biological activities of CIRP.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is a polyclonal antibody.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 8 (depends on 1)

The method of claim 1, wherein the antibody is a chimeric antibody, humanized antibody or human antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antibody is a single chain antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the CIRP inhibitor is a CIRP antisense molecule that reduces expression of CIRP.

### Claim 11 (depends on 1)

The method of claim 1, wherein the CIRP inhibitor has molecular weight less than 1000 Daltons.

### Claim 12 (depends on 1)

The method of claim 1, wherein the CIRP inhibitor is a peptide that specifically binds to CIRP and inhibits one or more biological activities of CIRP.

### Claim 13 (depends on 12)

The method of claim 12, wherein the peptide is a CIRP-derived peptide.

### Claim 14 (depends on 13)

The method of claim 13, wherein the CIRP-derived peptide is an antigenic fragment of CIRP.